These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37901630)

  • 1. A Case of Binocular Metastatic Choroidal Tumor Originating from Pulmonary Adenocarcinoma Successfully Treated with Molecular Target Therapy.
    Yamaoka M; Igarashi T; Shiratori N; Miyadera K; Sugano T; Noro R; Takahashi H
    Case Rep Ophthalmol; 2023; 14(1):426-432. PubMed ID: 37901630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of choroid metastasis from lung adenocarcinoma with bevacizumab-containing chemotherapy: A case report.
    Makabe K; Kurishima K; Shiozawa T; Miyazaki K; Ohara G; Kagohashi K; Satoh H; Hizawa N
    Exp Ther Med; 2016 Jan; 11(1):239-242. PubMed ID: 26889247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.
    Chiba S; Akiyama M; Yakuwa K; Sato H; Hirano K; Utsumi Y; Nagashima H; Sugai T; Maemondo M
    Ann Palliat Med; 2022 Aug; 11(8):2745-2750. PubMed ID: 34806395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyrosine Kinase Inhibitors in the Treatment of Choroidal Metastases from Non-Small-Cell Lung Cancer: A Case Report and Review of Literature.
    Nair AG; Asnani HT; Mehta VC; Mehta SV; Pathak RS; Palkar AH; Gopinathan I
    Ocul Oncol Pathol; 2017 Jan; 3(1):28-33. PubMed ID: 28275600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Changes in Bilateral Choroidal Metastasis from Non-Small Cell Lung Cancer with Response to Afatinib: A Case Report.
    Zhou HP; Tanaka R; Tsuji H
    Ocul Immunol Inflamm; 2020 Aug; 28(6):860-863. PubMed ID: 31013174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.
    Huang YH; Hsu KH; Chin CS; Tseng JS; Yang TY; Chen KC; Su KY; Yu SL; Chen JJW; Chang GC
    Cancer Res Treat; 2022 Apr; 54(2):434-444. PubMed ID: 34352999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports.
    Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F
    Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
    Tamura T; Kawakado K; Makimoto G; Nakanishi M; Kuyama S
    Thorac Cancer; 2021 Jun; 12(11):1770-1774. PubMed ID: 33942527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series.
    Li SH; Hsieh MH; Fang YF
    Medicine (Baltimore); 2015 Oct; 94(41):e1739. PubMed ID: 26469914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab.
    Tamiya M; Kunimasa K; Nishino K; Matsumoto S; Kawachi H; Kuno K; Inoue T; Kuhara H; Imamura F; Goto K; Kumagai T
    Invest New Drugs; 2021 Feb; 39(1):232-236. PubMed ID: 32556898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
    Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.
    Mariachiara M; Celeste R; Federico F; Nicole B; Antonio C
    Int Ophthalmol; 2018 Dec; 38(6):2669-2675. PubMed ID: 29071523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.
    Abe M; Osoegawa A; Karashima T; Takumi Y; Kobayashi R; Hashimoto T; Miyawaki M; Takeuchi H; Okamoto T; Sugio K
    Int Cancer Conf J; 2019 Apr; 8(2):81-85. PubMed ID: 31149553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with
    Muto S; Ozaki Y; Okabe N; Matsumura Y; Hasegawa T; Shio Y; Hashimoto Y; Suzuki H
    Case Rep Oncol; 2020; 13(3):1387-1392. PubMed ID: 33442360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.
    Lee SH; Lin YC; Chiu LC; Ju JS; Tung PH; Huang AC; Li SH; Fang YF; Chen CH; Kuo SC; Wang CC; Yang CT; Hsu PC
    Ther Adv Med Oncol; 2022; 14():17588359221113278. PubMed ID: 35898964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
    Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
    BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.